Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer

NCT ID: NCT04756765

Last Updated: 2025-08-17

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE2
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-02-23
• Study Completion Date: 2024-12-18

Brief Summary

This purpose of this study is to test if talazoparib is safe and evaluate its response to advanced breast cancer associated with mutation of gene called PALB.

Detailed Description

Primary Objectives: To evaluate whether talazoparib monotherapy can induce a 30% rate of objective response in subjects with advanced breast cancer associated with a PALB2 mutation.

Secondary Objective(s)

1. To evaluate the safety of talazoparib in subjects with advanced PALB2 mutation associated breast cancer

2. To evaluate the progression free survival (PFS) of talazoparib monotherapy in subjects with advanced PALB2 mutation associated breast cancer

3. To evaluate the clinical benefit rate (CBR) of talazoparib monotherapy in subjects with advanced PALB2 mutation associated breast cancer

4. To evaluate the ability of circulating tumor DNA (ctDNA) to identify and characterize the nature of PALB2 mutations at baseline and upon progression in subjects with advanced PALB2 mutation associated breast cancer treated with talazoparib monotherapy

5. To evaluate patient reported quality of life on talazoparib monotherapy

Conditions

Breast Cancer; Advanced Breast Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Talazoparib Arm

Talazoparib 1 mg/day for 24 cycles (28 days per cycle), continuing until withdrawn or discontinued, eg, until RECIST 1.1 progression or unacceptable toxicity.

Group Type: EXPERIMENTAL

Talazoparib Tosylate

Intervention Type: DRUG

Talazoparib1 mg/day is to be administered orally on a continuous dosing schedule.

Interventions

Talazoparib Tosylate

Talazoparib1 mg/day is to be administered orally on a continuous dosing schedule.

Intervention Type: DRUG

Other Intervention Names

Talzenna; BMN-673

Eligibility Criteria

Inclusion Criteria

1. Histologically confirmed metastatic or recurrent HER2 negative breast cancer (IHC or fluorescence in situ hybridization (FISH) per ASCO/CAP guidelines).

2. Deleterious or suspected deleterious mutation in PALB2 assessed by Clinical Laboratory Improvement Amendments (CLIA) approved tumor next generation sequencing (NGS) or germline assay.

3. Women and men ≥ 18 years of age.

4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

5. All clinically significant toxic effects of prior cancer therapy resolved to Grade ≤ 1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE, v 5.0), except alopecia and G2 neuropathy.

6. Measurable disease per RECIST v1.115 (CT CAP with contrast and bone scan or positron emission tomography computer tomography (PET/CT) with IV contrast needed within 28 days of Cycle 1 Day 1. If patients have a history of brain metastases, a MRI brain or CT head with contrast is required).

7. A minimum 21 day wash out from previous treatment is required.

8. No evidence of progression on platinum (e.g., carboplatin or cisplatin) or within 8 weeks of last platinum dose

9. Adequate hematologic function

• Absolute neutrophil count (ANC) ≥ 1,500 cells/μL (≥ 1,500/mm3)
• Hemoglobin ≥ 9.0 g/dL with last transfusion at least 14 days before Day 1 of study drug
• Platelets ≥ 100,000 cells/μL (≥ 100,000/mm3)

10. Adequate hepatic function

• Bilirubin ≤ 1.5 times the specific institutional upper limit of normal (ULN). Exception: If Gilbert's syndrome; then ≤ 5 times ULN.
• Aspartate transaminase (AST) and alanine transaminase (ALT) each ≤ 2.5 x ULN; if liver function abnormalities are due to hepatic metastasis, then AST and ALT ≤ 5 x ULN

11. Adequate renal function

• Serum creatinine ≤ 1.5 x ULN; or
• Calculated creatinine clearance > 50 mL/min using the Cockcroft Gault formula.

12. Able to take oral medications

13. Received 0 3 prior therapies for advanced disease

14. Women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test and be willing to have additional urine pregnancy tests during the study. Women considered not of childbearing potential include those who have had no menstrual period for at least 1 year and have an estradiol in the postmenopausal range, or had tubal ligation at least 1 year prior to screening, or who have had total hysterectomy or bilateral oophorectomy.

15. WOCBP must agree to use effective contraception as of C1D1 and for 3 months after the last dose.

16. Male participants and their female partners of child bearing potential must be willing to use an appropriate method of contraception during the study and for 3 months after the last dose.

17. Willing and able to provide written, signed informed consent after the nature of the study has been explained, and prior to any research related procedures

18. Willing and able to comply with all study procedures

19. Adequate archival or fresh tumor sample from metastatic biopsy site; archival tumor from the primary breast tumor may be submitted if metastatic biopsy is not available and/or infeasible

Exclusion Criteria

1. Breast cancer amenable to curative treatment.

2. Prior treatment with a PARP inhibitor.

3. Deleterious or suspected deleterious germline or somatic BRCA1 or BRCA2 gene mutation. Patients with variants of unknown significance will be eligible.

4. Active Brain metastases OR leptomeningeal carcinomatosis. EXCEPTION: Adequately treated brain metastases documented by baseline CT or MRI scan that have not progressed since previous scans and do not require corticosteroids (prednisone 5 mg/day or equivalent allowed) for management of central nervous system (CNS) symptoms. A repeat CT or MRI following the identification of CNS metastases (obtained at least 2 weeks after definitive therapy) must document adequately treated brain metastases.

5. Pregnant or breastfeeding patients.

6. Other malignancy that is either active or for which patient has received treatment in the last three years excluding non melanoma skin cancer and carcinoma in situ of the cervix or breast.

7. Known active hepatitis B or hepatitis C.

8. Investigational agents within 28 days of C1D1.

9. Radiation therapy within 14 days of C1D1.

10. Major surgery within 21 days of C1D1.

11. Concurrent disease or condition that would interfere with study participation or safety, such as any of the following:

a. Active, clinically significant infection either grade > 2 by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 or requiring the use of parenteral anti microbial agents within 7 days of C1D1.

12. Clinically significant bleeding diathesis or coagulopathy.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Pfizer

INDUSTRY

Sponsor Role: collaborator

Stanford University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Melinda Telli

Role: PRINCIPAL_INVESTIGATOR

Stanford Universiy

Locations

Stanford University

Stanford, California, United States

Countries

United States

Other Identifiers

BRS0126

Identifier Type: OTHER

Identifier Source: secondary_id

NCI-2023-01961

Identifier Type: REGISTRY

Identifier Source: secondary_id

IRB-59141

Identifier Type: -

Identifier Source: org_study_id